Novartis shifts its focus to star cancer drugs

Article Abstract:

Novartis AG plans to build on the success of its cancer drug Gleevac, by outlining a pipeline of drug compounds now in clinical development that it hopes will make it an oncology drug leader by the middle of the decade.

Abstract

---

Novartis drug gets approval for lengthy cancer treatment

Article Abstract:

Novartis AG's Femara, a drug for treating early cases of breast cancer, has been approved for use in Switzerland. Femara has been found to reduce the recurrence of breast-cancer following surgery by 42%. It has already been approved in Mexico and other South American countries, and is expected to be approved soon in the U.S. and throughout Europe.

Europe, Sales, profits & dividends, South America, International aspects, Company sales and earnings, Breast cancer, Company earnings/profit, Femara (Medication)

---

Expiration date: Merck pulls Vioxx from market after link to heart problems

Article Abstract:

Pharmaceutical company Merck & Co. is hit hard by the recall of an arthritis drug that accounted for 11% of its global sales in 2003. Merck shares plunged by 27% following the announcement of the recall, raising questions as to the future of the already struggling company.

Product standards, safety, & recalls, Management dynamics, Executive changes & profiles, Securities issued, listed, Health aspects, Management, Officials and employees, Product defects and recalls, Securities, COX-2 inhibitors, Powers and duties, Arthritis, Company business management, Company securities, United States. Food and Drug Administration, Vioxx (Medication), Merck & Company Inc., Gilmartin, Raymond

Similar abstracts:

• Abstracts: Apple Computer provides market a sweet surprise in profit, sales. Apple reports its first loss in three years
• Abstracts: Debate on the Hong Kong tax base: its criteria, principles, and problems. Compliance costs of corporate taxation in Hong Kong
• Abstracts: Trying times: Tempus profit falls as advertising market softens. DoubleClick seeks acquisition targets, citing softer prices
• Abstracts: National Stadium: Keeps twin towers, but no retractable roof. Arup 'shafted' in Hull sports stadium copyright wrangle
• Abstracts: A hell of an operating system: the reasons for investigating Microsoft, and for not rushing to judgment. A lucky escape

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.